Solid Organ Transplants Caused by COVID-19 Infection and the Outcome of Transplantation Post-COVID-19: A Systematic Review

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 428 - 428

Published: Feb. 10, 2025

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has imposed several medical and economic challenges since its onset in 2019. This is due to ability target the respiratory system as well other organs, resulting significant impacts necessitating organ transplants. Our goal compile information from existing literature investigate how COVID-19 affects outcomes following transplantation. A comprehensive search was conducted studies reporting post-COVID-19 complications. We included 45 data related solid transplants, where either recipient, organ, or donor affected by SARS-CoV-2. majority of concluded that transplantation infection could be performed safely with similar non-COVID-19 patients, regardless whether donor, recipient COVID-19. No deviation standard immunosuppression regimens surgical protocols necessary either, further re-assuring feasibility these transplants viable treatment options. applies involving lungs, kidneys, liver, heart. However, there a limited number some areas, which warrants need for additional research order reach more concrete conclusions pertaining COVID-19’s effect on

Language: Английский

---

Multidisciplinary Management Strategies for Long COVID: A Narrative Review

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: May 1, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of infections to date and led a worldwide pandemic. Most patients had complete recovery from the infection, however, large number affected individuals experienced symptoms that persisted more than 3 months after diagnosis. These most commonly include fatigue, memory difficulties, brain fog, dyspnea, cough, other less common ones such as headache, chest pain, paresthesias, mood changes, muscle weakness, skin rashes, cardiac, endocrine, renal hepatic manifestations. The treatment this remains challenging. A multidisciplinary approach address combinations affecting multiple organ systems been widely adopted. This narrative review aims bridge gap surrounding broad approaches by providing an overview management strategies for long COVID conditions.

Language: Английский

---

Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals

Advances in Therapy, Journal Year: 2024, Volume and Issue: 42(2), P. 666 - 719

Published: Dec. 16, 2024

Language: Английский

---

Phage Therapy in Lung Transplantation: Current Status and Future Possibilities

Clinical Infectious Diseases, Journal Year: 2023, Volume and Issue: 77(Supplement_5), P. S416 - S422

Published: Nov. 1, 2023

Patients with chronic lung disease and transplantation have high rates of colonization infection from multidrug-resistant (MDR) organisms. This article summarizes the current state knowledge regarding phage therapy in setting transplantation. Phage has been used several transplant candidates recipients on a compassionate use basis targeting mostly MDR gram-negative infections atypical mycobacterial demonstrated clinical safety. biodistribution given intravenously or via nebulization not extensively studied, though preliminary data are presented. interacts both innate adaptive immune system; literature demonstrates development serum neutralization some cases therapy, although impact seems variable. A summary trials involving patients is presented, none specifically recipients. In addition to treatment active infections, variety scenarios may benefit well-designed this vulnerable patient population needed: pre- peritransplantation organism lead waitlisting currently declined by many centers, along potential reduction waitlist mortality posttransplant infections; be for biofilm-related bronchial stent and, finally, there possibility that can affect allograft function rejection.

Language: Английский

---

A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19

Clinical Transplantation, Journal Year: 2024, Volume and Issue: 38(9)

Published: Sept. 1, 2024

ABSTRACT Introduction Lung transplantation has become increasingly utilized in patients with COVID‐19. While several single‐center and UNOS database studies have been published on lung transplants (LTs) for end‐stage disease (ESLD) from Coronavirus 2019 (COVID‐19), there is a lack of multi‐center international data. Methods This multicenter analysis 11 high‐volume transplant centers the United States Europe. Data were collected through Multi‐Institutional ECLS Registry stratified by ESLD due to COVID‐19 versus other etiologies. Demographics clinical variables compared using Chi‐square test Fisher's exact test. Survival was assessed Kaplan‐Meier curves log‐rank propensity score matching. Results Of 1606 recipients, 46 (2.9%) transplanted 1560 (97.1%) without history Among patients, 30 (65.2%) had COVID‐19‐associated ARDS 16 (34.8%) post‐COVID‐19 fibrosis. higher allocation scores (78.0 vs. 44.4, p < 0.0001), severely limited functional status (37.0% 2.9%, preoperative ECMO usage (65.2% 5.4%, spent less time waitlist (32 137 days, 0.0001). A 30‐day survival comparable between non‐COVID‐19 before (100% 98.7%, = 0.39) after matching ( 0.15). Conclusions Patients who received LTs short‐term that Our findings support idea should be considered select

Language: Английский

---

The impact of high volumes of COVID‐related lung transplant on waitlist mortality for non‐COVID candidates in the United States

Clinical Transplantation, Journal Year: 2024, Volume and Issue: 38(2)

Published: Feb. 1, 2024

Abstract Some patients with coronavirus disease 19 (COVID) develop serious, irreversible lung disease, including acute respiratory distress syndrome or pulmonary fibrosis. For select candidates, transplant is the only option to improve quality and length of life. Because severity end‐stage COVID‐related these candidates receive high allocation priority in United States, higher than many without disease. This study assessed whether centers a large volume transplants experienced an increase waitlist mortality for non‐COVID candidates. Nineteen were included as high‐volume programs, defined being top third who transplanted COVID patients. Of 2867 waitlisted at centers, there was no significant difference mortalities between pre‐COVID era (January 2018–February 2020) during period (March 2020–October 2022) (subhazard ratio: .92 [95% CI = .81–1.05], p .22). Among decision prioritize did not significantly impact other

Language: Английский

---

Lessons Learned From Extracorporeal Life Support Practice and Outcomes During the COVID‐19 Pandemic

Clinical Transplantation, Journal Year: 2024, Volume and Issue: 38(11)

Published: Oct. 29, 2024

ABSTRACT Extracorporeal membrane oxygenation is increasingly being used to support patients with hypoxemic respiratory failure and cardiogenic shock. During the COVID‐19 pandemic, consensus guidance recommended extracorporeal life for COVID‐19‐related cardiopulmonary disease refractory optimal conventional therapy, prompting a substantial expansion in use of this modality. was particularly integral bridging heart or lung transplantation. Limited human physical resources precluded widespread utilization mechanical during necessitating careful patient selection management by expert healthcare teams judicious use. This review outlines evidence supporting COVID‐19, describes practice outcomes shock, proposes lessons learned implementation as bridge transplantation future public health emergencies.

Language: Английский

---

Clinician Commentary on Brunne et al.

Physiotherapy Canada, Journal Year: 2023, Volume and Issue: 75(4), P. 357 - 358

Published: Nov. 27, 2023

Language: Английский

---